Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Management of COVID19-Associated Lung Injury: A Review on Publications, Clinical Trials and Patent Landscape
Authors:
- 6 April 2022
- journal article
- review article
- Published by Springer Nature in Tissue Engineering and Regenerative Medicine
- Vol. 19 (4) , 659-673
Abstract
The unprecedented COVID-19 pandemic situation forced the scientific community to explore all the possibilities from various fields, and so far we have seen a lot of surprises, eureka moments and disappointments. One of the approaches from the cellular therapists was exploiting the immunomodulatory and regenerative potential of mesenchymal stromal cells (MSCs), more so of MSC-derived extracellular vesicles (EVs)—particularly exosomes, in order to alleviate the cytokine storm and regenerate the damaged lung tissues. Unlike MSCs, the EVs are easier to store, deliver, and are previously shown to be as effective as MSCs, yet less immunogenic. These features attracted the attention of many and thus led to a tremendous increase in publications, clinical trials and patent applications. This review presents the current landscape of the field and highlights some interesting findings on MSC-derived EVs in the context of COVID-19, including in silico, in vitro, in vivo and case reports. The data strongly suggests the potential of MSC-derived EVs as a therapeutic regime for the management of acute lung injury and associated complications in COVID-19 and beyond. Graphical abstractKeywords
Funding Information
- Anusandhan National Research Foundation (CVD/2020/000224)
This publication has 117 references indexed in Scilit:
- Influenza A Viruses Target Type II Pneumocytes in the Human LungThe Journal of Infectious Diseases, 2012
- Mesenchymal stem cells enhance survival and bacterial clearance in murineEscherichia colipneumoniaThorax, 2012
- Allogeneic Human Mesenchymal Stem Cells Restore Epithelial Protein Permeability in Cultured Human Alveolar Type II Cells by Secretion of Angiopoietin-1*Journal of Biological Chemistry, 2010
- Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2009
- Use of Senescence-Accelerated Mouse Model in Bleomycin-Induced Lung Injury Suggests That Bone Marrow-Derived Cells Can Alter the Outcome of Lung Injury in Aged MiceThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2009
- Characterization of exosome‐like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defenseThe FASEB Journal, 2009
- Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseasesThrombosis and Haemostasis, 2008
- Immunosuppression by Placental Indoleamine 2,3-Dioxygenase: A Role for Mesenchymal Stem CellsPlacenta, 2007
- Early Enhanced Expression of Interferon-Inducible Protein-10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute Respiratory SyndromeClinical Chemistry, 2005
- The Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003